FDA asks SkyePharma to do more clinical work on Flutiform

The Food and Drug Administration has asked SkyePharma Plc to provide more clinical data for its asthma treatment, Flutiform, thereby extending its review of the Flutiform new drug application (NDA) into 2011, the UK company said.